Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series

Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Jing Jin, Matthew Bonaparte, Carina Fargo, Alain Bouckenooghe, Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Jing Jin, Matthew Bonaparte, Carina Fargo, Alain Bouckenooghe

Abstract

The tetravalent dengue vaccine (CYD-TDV; Dengvaxia®) is administered on a three-dose schedule, 6 months apart in those aged ≥9 years in a number of dengue-endemic countries in Asia and Latin America. In this study, CYD63 (NCT02824198), participants aged 9-45 years at first vaccination, and who had received three doses of CYD-TDV in the CYD28 study more than 5 years previously, were randomized 3:1 to receive a booster CYD-TDV dose (Group 1) or placebo (Group 2). Dengue neutralizing antibody geometric mean titres (PRNT50 GMTs) for each of the four dengue serotypes were assessed in sera collected before and 28 days after booster injections. Non-inferiority of the booster immune response versus that induced after the third dose was demonstrated for each serotype if the lower limit of the two-sided 95% confidence interval (CI) was >0.5 for the GMT ratios (GMTRs) between post-booster CYD-TDV dose and post-dose 3 in Group 1. Overall, 118 participants received CYD-TDV booster or placebo and 116 (98.3%) completed the study; two participants were withdrawn because of noncompliance. GMTs in the booster CYD-TDV group increased across all serotypes post-booster injection by 1.74- (serotype 1) to 3.58-fold (serotype 4). No discernible increases were observed in the placebo group. Non-inferiority was demonstrated for serotypes 1, 3, and 4, but not for serotype 2 (GMTR; 0.603 [95% CI, 0.439- 0.829]). No safety issues were observed. These data show that the CYD-TDV booster given 5 or more years later tended to restore GMTs back to levels observed post-dose 3.

Keywords: CYD-TDV; Singapore; booster vaccine; dengue; tetravalent.

Figures

Figure 1.
Figure 1.
Geometric mean titers and 95% confidence intervals for each dengue serotype at pre-booster (●) and 28 days post-booster (□) injection in the CYD-TDV group (a) and placebo group (b) by dengue serostatus at baseline in CYD28 (per-protocol analysis set). PRNT50: 50% plaque reduction neutralization test

References

    1. World Health Organization . Dengue and severe dengue [Fact sheet]; 201. 9. .
    1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, et al. The global distribution and burden of dengue. Nature. 2013;496:504. doi:10.1038/nature12050.
    1. Thein S, Aung MM, Shwe TN, Aye M, Zaw A, Aye K, Aaskov J. Risk factors in dengue shock syndrome. Am J Trop Med Hyg. 1997;56:566–72. doi:10.4269/ajtmh.1997.56.566.
    1. Chau TN, Quyen NT, Thuy TT, Tuan NM, Hoang DM, Dung NTP, Lien LB, Quy NT, Hieu NT, Hieu LTM, et al. Dengue in Vietnamese infants–results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis. 2008;198:516–24. doi:10.1086/590117.
    1. World Health Organization . Dengue vaccine research. Immunization, vaccines and biologicals; 2019. .
    1. Ooi EE, Goh KT, Gubler DJ.. Dengue prevention and 35 years of vector control in Singapore. Emerg Infect Dis. 2006;12:887–93. doi:10.3201/10.3201/eid1206.051210.
    1. Rajarethinam J, Ang L-W, Ong J, Ycasas J, Hapuarachchi HC, Yap G, Chong C-S, Lai Y-L, Cutter J, Ho D, et al. Dengue in Singapore from 2004 to 2016: cyclical epidemic patterns dominated by serotypes 1 and 2. Am J Trop Med Hyg. 2018;99:204–10. doi:10.4269/ajtmh.17-0819.
    1. Hapuarachchi HC, Koo C, Rajarethinam J, Chong CS, Lin C, Yap G, et al. Epidemic resurgence of dengue fever in Singapore in 2013–2014: A virological and entomological perspective. BMC Infect Dis. 2016;16:300. doi:10.1186/s12879-016-1987-z.
    1. Health Sciences Authority, Singapore Government . HSA approves dengvaxia vaccine; 2016. .
    1. Health Sciences Authority, Singapore Ministry of Health . HSA further updates on dengvaxia®. Singapore, Asia; 2017. .
    1. Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, Savarino S, Zambrano B, Moureau A, Khromava A, Moodie Z. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379:327–40. doi:10.1056/NEJMoa1800820
    1. Leo YS, Wilder-Smith A, Archuleta S, Shek LP, Chong CY, Leong HN, Low CY, Oh M-LH, Bouckenooghe A, Wartel TA, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 y: phase II randomized controlled trial in Singapore. Hum Vaccin Immunother. 2012;8:1259–71. doi:10.4161/hv.21224.
    1. Vigne C, Dupuy M, Richetin A, Guy B, Jackson N, Bonaparte M, Hu B, Saville M, Chansinghakul D, Noriega F, et al. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination. Hum Vaccin Immunother. 2017;13:2004–16. doi:10.1080/21645515.2017.1333211.
    1. Coronel D, García E, Rivera-Medina MD, Arredondo JL, Dietze R, Villar L, Perroud A, Cortes M, Bonaparte M, Hawk W, et al. Dengue vaccine booster in healthy adolescents and adults 4 to 5 years after a 3-dose primary schedule in Latin America. Cancún (México): SLIPE congress; 2017.
    1. World Health Organization . Dengue vaccine: WHO position paper – September 2018. Wkly Epidemiol Record 2018;36:457–76.
    1. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai school children: a randomised, controlled phase 2b trial. Lancet. 2012;380:1559–67. doi:10.1016/S0140-6736(12)61428-7.
    1. Capeding MR, Laot TM, Boaz M, Wartel TA, Crevat D. Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period. Trials Vaccinol. 2015;4:19–23. doi:10.1016/j.trivac.2015.03.002.
    1. Olivera-Botello G, Coudeville L, Fanouillere K, Guy B, Chambonneau L, Noriega F, Jackson N. Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue virus infections in healthy children and adolescents aged 2–16 years in Asia and Latin America. J Infect Dis. 2016;214:994–1000. doi:10.1093/infdis/jiw297.
    1. Timiryasova TM, Bonaparte MI, Luo P, Zedar R, Hu BT, Hildreth SW. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg. 2013;88:962–70. doi:10.4269/ajtmh.12-0461.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir